This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Human Umbilical Vein Endothelial Cells (HUVEC) Market

Human Umbilical Vein Endothelial Cells (HUVEC) Market

Human Umbilical Vein Endothelial Cells (HUVEC) Market, Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2021 to 2031

Human Umbilical Vein Endothelial Cells (HUVEC) Market
FACT6216MR
  • May-2021
  • List of Tables : 25
  • List of Figures : 132
  • 170 Pages
  • Healthcare

Key Questions Answered in Report

  • Which is the most promising application area for human umbilical vein endothelial cells (HUVEC)?

According to Fact.MR, the oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, attributed to their purported effectiveness in targeting malignant growth. Simultaneously, uptake across tissue culture is also likely to widen in the future.

  • Which countries are likely to offering promising expansion prospects for HUVEC through 2031?

The U.S. and Indian markets are expected to provide immense growth opportunities for HUVEC, as both countries are making significant strides in furthering good quality healthcare across key domains as CVD and cancer treatment.

  • Which prominent players are operating within the global HUVEC landscape?

Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.

Report Also Addresses:

  • Market Estimates and Forecasts (2016-2031)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand Share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on HUVEC Market and How to Navigate
  • Recommendation on Key Winning Strategies

Know More Details About the Report

Human Umbilical Vein Endothelial Cells 2016 to 2020 Trends Vs Projections for 2021 to 2031

From 2016 to 2020, demand for human umbilical vein endothelial cell-based treatment has been gradually gaining momentum, as advancements in genetic engineering and biotechnology become increasingly overt. Extensive applications are being witnessed in the oncology domain, followed by tissue culture and angiogenesis.

Growth of the market remained consistent across the COVID-19 pandemic, although initial shocks were experienced in the first half of 2020, attributed to reduced hospital visits amid fears of contracting the novel coronavirus infection. Future prospects are extremely lucrative, especially across emerging economies across Asia as spending on healthcare infrastructure augments.

How is Surging Tissue Engineering Popularity Augmenting Adoption of Human Umbilical Vein Endothelial Cells?

Over the years, tissue engineering has acquired immense popularity, being deployed across a broad spectrum of treatment domains. Tissue engineering provides alternatives to surgical reconstruction, transplants, and other mechanical devices that are used to repair damaged tissues.

The market for tissue engineering is also driven by a continuous increase in the need for effective regenerative treatments owing to a rise in the prevalence of diabetes, obesity, and other disorders due to lifestyle changes, aging population, and growing trauma cases. Hence, demand for human umbilical vein endothelial cells based treatment is garnering significant momentum.

Avail customized purchase options for your needs

What is the Scope of HUVEC in Angiogenesis?

Angiogenesis using human umbilical vein endothelial cells is proving highly beneficial to address hepatocellular carcinoma (HCC), a typical hyper-vascular tumour. Hepatocellular carcinoma is a debilitating form of liver cancer which typically arises post a severe Hepatitis B or C infection.

Hence, prominent healthcare providers are leveraging advanced treatment and diagnosis approaches to address this condition. Hepatocellular carcinoma is an aggressive malignancy, resulting as the third cause of death by cancer each year. The management of patients with HCC is complex, as both the tumour stage and any underlying liver disease must be considered conjointly.

human umbilical vein endothelial cells huvec market

Country-wise Analysis

How Bright are HUVEC Growth Prospects across the U.S.?

HUVEC-based treatment adoption rate in the U.S. is expanding rapidly to treat cardiovascular diseases. Several studies have established that HUVECs are a highly useful model for research on human endothelium, and is effective in examining the pathophysiological mechanisms involved in the onset of CVDs.

Additionally, this approach is being increasingly incorporated in the diagnosis and treatment of various forms of cancers. Furthermore, these cells are also being incorporated in angiogenesis to study ovulation, inflammation and tumour growth patterns.

Why is India Considered a Lucrative Market for HUVEC Players?

In recent years, India has generated a fertile space for cell culture- and tissue culture-based treatment. As biotechnology acquires rapid pace in the country, numerous initiatives are being undertaken to further its applications across the broad spectrum of treatment areas.

As per data published by India Against Cancer, around 2.25 million people are afflicted with the disease, with new patients amounting to over a million every year. Hence, major companies are accelerating efforts to discover potent treatments, elevating prospects for HUVEC based treatment.

An Adaptive Approach to Modern-day Research Needs

Category-wise Insights

How are Pooled Donor HUVECs Generating Demand?

By type, pooled donor HUVECs are acquiring significant popularity, and the segment is projected to expand at more than 10% CAGR through 2031, attributed to their ability to reduce donor variability so as to provide a uniform and consistent application standard to key genetic research platforms.

Players such as Lonza offer a series of cryopreserved HUVECs, shipped as frozen primaries, which are pooled donor and single donor based. Their XL size consists of 10 million cells/ampoule which are achieved by pooling donors.

Which is the Primary Application Area of HUVECs?

HUVECs for oncology and cancer treatment are expected to find immense applications over the decade, with the segment expected to surge ahead at 12%-15% CAGR, as prominent healthcare settings leverage the latest cell technology to eradicate the disease.

For instance, HUVEC-docetaxel (DOC) treatment has been proven to make significant breakthroughs with respect to breast cancer treatment, exhibiting more favourable anti-EMT-6 breast cancer effects in vivo.

Competitive Landscape

The HUVEC landscape appears highly consolidated, marked by the presence of a handful of service providers across prominent geographies. These players primarily concentrate on offering high-grade product offerings as their primary expansion strategy.

  • In December 2020, Corning Inc. launched the Corning® X-SERIES® cell processing platform which delivers fast, sterile, automated and efficient processing of human blood and blood products to obtain purified populations of immune cells for gene therapy applications
  • Thermo Fisher Scientific offers the GibcoTM HUVEC Adherent Cell Culture which is cryopreserved and tested for Hepatitis B (HBV), Hepatitis C (HCV), sterility testing (bacterial & fungi), mycoplasma, HIV-1 and as a growth performance assay

*This list is indicative- full details about prominent human umbilical endothelial cells providers is available upon request.

Have a report related query? Speak to us directly

Report Scope

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value & ‘000 Units for Volume

Key Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • France
  • U.K
  • Italy
  • Russia
  • Nordics
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Mexico
  • Brazil
  • GCC
  • Turkey

Key Segments Covered

  • Type
  • Application
  • Region

Key Companies Profiled

  • Lonza Group AG
  • PromoCell- Human Centered Science
  • Merck & Co. KGaA
  • Thermo Fisher Scientific
  • Lifeline
  • Corning Inc.

Pricing

Available upon Request

Key Market Segments Covered

  • Type

    • Single Donors of Human Umbilical Vein Endothelial Cells
    • Pooled Donors of Human Umbilical Vein Endothelial Cells
  • Application

    • Human Umbilical Vein Endothelial Cells for Wound Healing
    • Human Umbilical Vein Endothelial Cells for Angiogenesis
    • Human Umbilical Vein Endothelial Cells for Tissue Engineering
    • Human Umbilical Vein Endothelial Cells for Inflammation Treatment
    • Human Umbilical Vein Endothelial Cells for Oncology
    • Human Umbilical Vein Endothelial Cells for Other Applications
  • Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K
      • Italy
      • Russia
      •  Nordics
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • Australia
      • Rest of Asia Pacific
    • Latin America
      • Mexico
      • Brazil
      • Rest of Latin America
    • Middle East & Africa
      • GCC
      • Turkey
      • Rest of MEA

Human Umbilical Vein Endothelial Cells (HUVEC) Market - Scope of Report

A recent study by Fact.MR on the human umbilical vein endothelial cells (HUVEC) market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering human umbilical vein endothelial cells.

The study also provides the dynamics responsible for influencing the future status of the market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the HUVEC market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of human umbilical vein endothelial cells across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of HUVEC during the forecast period. Price point comparison by region with global average price is also considered in the study.

Key Questions Answered in Report

  • Which are the most lucrative markets for human umbilical vein endothelial cells?
  • Which factors will impact the growth of the market over the coming years?
  • How will changing trends impact the strategies of market players?
  • How can market players capture the low-hanging opportunities across regions?
  • Which companies are leading the human umbilical vein endothelial cells industry?
  • What are the winning strategies of stakeholders in the market?

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Market estimates at global and regional levels for human umbilical vein endothelial cells are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global HUVEC market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the HUVEC market during the forecast period.

Country-specific valuation on demand for human umbilical vein endothelial cells has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value and volume for emerging countries has also been included in the report.

In-depth Analysis on Competitive Landscape

The report sheds light on leading manufacturers of human umbilical vein endothelial cells, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering human umbilical vein endothelial cells has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the HUVEC market, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

- FAQs -

According to Fact.MR, the human umbilical vein endothelial cells market is projected to surge ahead at approx. 10% CAGR through 2031, with the growth rate even higher in Western countries as compared to other parts of the world.
The oncology segment is anticipated to accrue highly lucrative gains to the human umbilical vein endothelial cells (HUVEC) market, expanding at close to 15% CAGR over the next ten years, attributed to their purported effectiveness in targeting malignant g
North America, especially the U.S., and Europe, are expected to account for more than 40% market share, and are expected to provide immense growth opportunities for HUVEC, as both regions are making significant strides in furthering good quality healthcar
Some of the prominent players involved in human umbilical vein epithelial cells include Lonza Group AG, PromoCell- Human Centered Science, Merck & Co. KGaA, Thermo Fisher Scientific, Lifeline, and Corning Inc.

Need an Exclusive Report for your Unique Requirement?

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.